Introduction to Iterum Therapeutics Ltd. USA
Iterum Therapeutics Ltd. USA is a clinical-stage biopharmaceutical company committed to developing novel antibiotics to address the growing global threat of multidrug-resistant infections. Headquartered in Chicago, Illinois, with a strong operational presence across the United States, the company leverages decades of scientific expertise and a robust pipeline of therapeutics targeting both community-acquired and hospital-acquired infections. As a recognized leader in the healthcare and pharmaceutical industry, Iterum Therapeutics Ltd. USA has garnered attention for its innovative approach to anti-infective drug development, specifically its lead compound sulopenem, a broad-spectrum oral and intravenous penem antibiotic.
The company's reputation is built on a foundation of rigorous clinical research, strategic partnerships with academic institutions, and a unwavering commitment to patient safety. Iterum Therapeutics Ltd. USA attracts top-tier talent from the pharmaceutical, biotechnology, and medical fields, and its work is closely monitored by investors, regulatory agencies, and healthcare providers worldwide. With a market capitalization reflecting its promising pipeline and a team of over 200 dedicated employees, Iterum stands at the forefront of the battle against antimicrobial resistance (AMR). This profile provides an in-depth look at the company’s history, culture, and the compelling career opportunities it offers, including the featured Senior Clinical Research Associate position.
Company History and Business Evolution
Iterum Therapeutics Ltd. USA traces its origins to the founding of Iterum Therapeutics plc in Ireland in 2016, with a mission to develop next-generation antibiotics that overcome resistance mechanisms seen in Gram-negative, Gram-positive, and anaerobic bacteria. The US subsidiary was established shortly thereafter to spearhead clinical operations and regulatory affairs in the world’s largest pharmaceutical market. From the outset, the company focused on sulopenem, a compound that originally emerged from the research laboratories of Pfizer and later licensed by Iterum. This strategic acquisition allowed Iterum to bypass early-stage discovery risks and proceed directly to clinical development.
In 2017, Iterum raised significant capital through a Series A financing round, followed by a successful IPO on the Nasdaq in 2018 under the ticker symbol ITRM. The proceeds fueled a comprehensive Phase 3 clinical program for sulopenem in uncomplicated urinary tract infections (uUTI), complicated UTI (cUTI), and complicated intra-abdominal infections (cIAI). Over the next five years, Iterum reported positive top-line results from multiple trials, including the SURE 1, SURE 2, and REASSURE studies, demonstrating the efficacy and safety of sulopenem against resistant pathogens. The company also expanded its pipeline to include additional formulations and combination therapies, such as IV sulopenem and the oral prodrug sulopenem etzadroxil.
Despite the challenges inherent in antibiotic development—including regulatory hurdles and market access issues—Iterum has persevered, supported by partnerships with the Biomedical Advanced Research and Development Authority (BARDA) and the Global Antibiotic Research and Development Partnership (GARDP). In 2023, the company submitted a New Drug Application (NDA) to the FDA for sulopenem in uUTI, marking a critical milestone. The US team, led by experienced executives from prominent pharma companies, has been instrumental in navigating the complex regulatory landscape. Today, Iterum Therapeutics Ltd. USA continues to advance its clinical programs while exploring new indications and formulations, positioning itself as a key player in the anti-infective space.
Iterum Therapeutics Ltd. USA at a Glance
- Headquarters: Chicago, Illinois, USA
- Global Parent Company: Iterum Therapeutics plc (Dublin, Ireland)
- Founded: 2016
- CEO: Corey Fishman
- Number of Employees: Approximately 220 (US and global)
- Revenue: Pre-revenue development-stage company; public filings indicate net losses of $50-70M annually (2023-2024)
- Market Cap: ~$80-120M (as of early 2025)
- Lead Product: Sulopenem (oral and IV formulations)
- Therapeutic Areas: Uncomplicated and complicated urinary tract infections, complicated intra-abdominal infections, community-acquired pneumonia
- Regulatory Status: NDA submitted to FDA for uUTI (2023-2024)
- Key Partnerships: BARDA, GARDP, academic medical centers
- Industry: Biopharmaceuticals / Anti-Infectives
- Stock Symbol: ITRM (Nasdaq)
- US Operations: Clinical operations, regulatory affairs, medical affairs, commercial planning
- Clinical Trials: Phase 3 complete for uUTI, ongoing for cUTI and cIAI
- AMR Focus: Targeted at ESBL-producing and multidrug-resistant bacteria
- Awards: Recognized by FDA for Qualified Infectious Disease Product (QIDP) designation
- Corporate Culture: Mission-driven, collaborative, patient-centric
- Job Opportunities: Clinical research, regulatory, medical writing, biostatistics, project management
- Location Advantage: Chicago hub offers access to top talent in pharma and biotech
Mission, Vision, and Core Corporate Values
Iterum Therapeutics Ltd. USA operates with a clear mission: to discover, develop, and deliver innovative antibiotic therapies that combat antimicrobial resistance and improve the lives of patients worldwide. The company envisions a future where effective, safe, and accessible antibiotics are available for all, even as resistance evolves. This vision drives every decision, from clinical trial design to regulatory strategy and potential commercial launch.
Core corporate values include scientific excellence, integrity, collaboration, and patient focus. Scientific excellence demands rigorous data generation and adherence to highest standards of clinical research. Integrity is reflected in transparent reporting and ethical interactions with regulators, investigators, and patients. Collaboration is emphasized internally across functions—research, development, regulatory, and commercial—as well as externally with partners and key opinion leaders. Patient focus ensures that all efforts are ultimately aimed at addressing unmet medical needs and improving outcomes for those suffering from serious bacterial infections.
These values are embedded in the company’s operating principles and are reinforced through team-building events, leadership communications, and performance evaluations. Employees at Iterum are encouraged to challenge assumptions, propose innovative solutions, and maintain a strong sense of urgency in the fight against superbugs. The corporate culture fosters a sense of purpose that extends beyond financial gains, making Iterum an attractive employer for professionals who want to make a tangible difference in global health.
Business Strategy and Future Roadmap
Iterum Therapeutics Ltd. USA’s business strategy centers on the successful commercialization of sulopenem across multiple indications, followed by expansion of its pipeline through internal research, in-licensing, and strategic collaborations. The immediate priority is to obtain FDA approval for sulopenem in uncomplicated urinary tract infections (uUTI), a massive market with over 10 million cases annually in the US alone. Upon approval, Iterum plans to build a lean, specialized sales force targeting urologists, primary care physicians, and infectious disease specialists. A value-based pricing strategy, aligned with antibiotics’ societal benefit and cost-saving potential, is being developed.
Longer-term, the company aims to secure approvals for additional indications such as complicated UTI and complicated intra-abdominal infections, thereby broadening the product’s label and revenue potential. Simultaneously, Iterum is exploring oral-only regimens and pediatric formulations to extend market reach. Recognizing the challenges of antibiotic commercialization—including limited reimbursement and inadequate pipeline replenishment—Iterum is actively engaging with policymakers to support initiatives like the PASTEUR Act, which would establish a subscription-based model for novel antibiotics. Internally, the company is investing in digital health technologies to enhance clinical trial efficiency and real-world evidence generation.
The roadmap also includes geographic expansion into Europe and Asia through licensing deals with local partners, leveraging the global parent company’s network. With a strong balance sheet (despite ongoing R&D spending) and a disciplined approach to capital allocation, Iterum is positioned to weather the valley of death that often plagues antibiotic developers. The US team will play a pivotal role in executing this strategy, from leading clinical studies to preparing launch readiness materials.
Products, Technologies, and Services
Iterum Therapeutics Ltd. USA’s primary product is sulopenem, a broad-spectrum penem antibiotic available in two formulations: sulopenem etzadroxil (oral prodrug) and sulopenem IV. Sulopenem is designed to overcome resistance mechanisms such as extended-spectrum beta-lactamases (ESBLs) and AmpC enzymes, making it effective against a wide range of aerobic and anaerobic Gram-positive and Gram-negative bacteria. The oral formulation in particular offers a significant advantage over current standard-of-care antibiotics, which often require intravenous administration for resistant infections.
Beyond sulopenem, Iterum’s pipeline includes next-generation beta-lactamase inhibitors and novel combinations that are still in preclinical stages. The company also possesses proprietary drug delivery technologies that enhance the stability and bioavailability of its compounds. Iterum does not currently offer services or diagnostics; its focus remains exclusively on therapeutic drug development. However, the company collaborates with contract research organizations (CROs), academic medical centers, and diagnostic companies to advance its clinical programs and companion diagnostics.
Through its clinical development services, Iterum provides trial participants and physicians access to innovative treatment options not yet available in the market. The company’s medical affairs team offers educational resources to healthcare providers about antimicrobial resistance and appropriate antibiotic use. While still a development-stage biotech, Iterum’s products have the potential to become essential tools in the armamentarium against multi-drug resistant infections.
Industries and Markets Served
Iterum Therapeutics Ltd. USA serves the healthcare industry, specifically the subsectors of infectious disease, hospital medicine, and primary care. Its target markets include hospitals, clinics, outpatient care centers, and nursing homes where complicated infections are prevalent. The company’s primary customers will be healthcare providers—physicians, nurse practitioners, and pharmacists—who prescribe antibiotics for bacterial infections. Additionally, payers (Medicare, Medicaid, commercial insurers) and pharmacy benefit managers (PBMs) are key stakeholders who influence access and reimbursement.
The global antibiotic market is large but fragmented, with an estimated value of over $40 billion annually. Within this market, the demand for novel antibiotics effective against resistant pathogens is growing, driven by increasing incidence of AMR. Iterum’s products target high-unmet-need areas such as uUTI caused by ESBL-producing E. coli, which now accounts for up to 15-20% of community-acquired UTIs in some regions. The company also serves a public health function by providing tools to combat AMR, aligning with WHO and CDC priorities. As the company matures, it plans to expand into international markets, particularly in Europe and Asia, where antibiotic resistance is even more pronounced.
Leadership and Management Philosophy
The leadership team of Iterum Therapeutics Ltd. USA comprises seasoned pharmaceutical executives with decades of experience in drug development, regulatory affairs, and commercial strategy. CEO Corey Fishman, previously at Melinta Therapeutics and other biotech firms, brings deep expertise in anti-infectives and a track record of advancing life-saving medicines. The US head, Dr. Susan Richards (SVP of Clinical Development), oversees all clinical operations and has led multiple successful Phase 3 programs. The management philosophy is grounded in transparency, data-driven decision-making, and a strong sense of mission. Leaders at Iterum prioritize open communication, cross-functional collaboration, and empowerment of individual contributors. Weekly all-hands meetings, quarterly town halls, and continuous feedback loops ensure that every employee feels informed and valued. The company also invests in leadership development programs to nurture the next generation of biotech leaders.
Corporate Events, Conferences, and Community Engagement
Iterum Therapeutics Ltd. USA actively participates in major medical and scientific conferences, including IDWeek, ASM Microbe, ECCMID, and MAD-ID. At these events, the company presents clinical data, hosts symposia, and engages with key opinion leaders to disseminate knowledge about sulopenem and AMR. The company also organizes internal research symposia and training workshops for employees and contracted investigators.
Community engagement is a priority: Iterum supports local STEM education initiatives in Chicago, partnering with high schools and universities to inspire careers in biotech. The company also sponsors awareness campaigns about antibiotic stewardship, often collaborating with public health agencies. Annual charity runs, blood drives, and volunteer days at food banks are part of the corporate social responsibility program. These activities not only strengthen community ties but also boost employee morale and retention.
Employees and Workplace Culture
Iterum Therapeutics Ltd. USA fosters a culture of innovation, respect, and inclusivity. The Chicago office offers a modern, open-plan workspace with collaborative zones, a wellness room, and fully stocked break areas. The company provides competitive compensation, including stock options, performance bonuses, and comprehensive health benefits (medical, dental, vision, mental health support). Flexible work arrangements, including hybrid schedules, accommodate work-life balance.
Employee resource groups (ERGs) for women in biotech, LGBTQ+ allies, and racial diversity promote belonging. Annual employee engagement surveys guide continuous improvement. Professional development is encouraged through tuition reimbursement, conference attendance, and internal training programs on clinical trial design, regulatory affairs, and leadership skills. The overall employee Net Promoter Score (eNPS) is strong, reflecting high levels of engagement and satisfaction. Turnover rates are below industry average, indicating a loyal and motivated workforce.
Job Details & Requirements for this Posting: Senior Clinical Research Associate
Position Title: Senior Clinical Research Associate (CRA) – Infectious Disease Studies
Location: Chicago, IL (hybrid – 2 days/week in office)
Employment Type: Full-time
Salary Range: $120,000 – $160,000 per year, depending on experience, plus bonus and stock options
Role Overview: The Senior CRA will be responsible for the operational oversight of Phase 3 clinical trials at Investigator sites across the US. This role ensures compliance with GCP, FDA regulations, and company SOPs while supporting the clinical team in achieving enrollment targets and data quality goals.
Responsibilities:
- Conduct site qualification, initiation, routine monitoring, and close-out visits for 15-20 active sites.
- Review and verify source documents, case report forms (CRFs), and electronic data capture (EDC) entries for accuracy and completeness.
- Oversee essential document management, including TMF filing and regulatory binder maintenance.
- Collaborate with CRO partners and internal team to resolve site issues and provide training.
- Serve as primary point of contact for site coordinators and principal investigators.
- Assist with site selection, feasibility assessments, and enrollment strategies.
- Support preparation of regulatory submissions (IND/NDA) by providing monitoring reports and data summaries.
- Mentor junior CRAs and contribute to process improvement initiatives.
Qualifications:
- Bachelor’s degree in life sciences, nursing, or related field; advanced degree preferred.
- Minimum 5 years of CRA experience, with at least 2 years at Senior level.
- Experience in infectious disease or antibiotic clinical trials highly desirable.
- Strong knowledge of ICH-GCP guidelines and FDA regulations.
- Willingness to travel up to 40% (domestic).
- Excellent communication, organizational, and problem-solving skills.
- Certification (CCRA or equivalent) is a plus.
Why Join Iterum Therapeutics Ltd. USA? This role offers the opportunity to be part of a groundbreaking antibiotic development program that could change the standard of care for resistant infections. You will work alongside passionate, accomplished colleagues who are dedicated to a common mission. Career growth potential is significant as the company moves toward commercialization. You will gain exposure to regulatory interactions and cross-functional collaboration. Additionally, the company offers a supportive work culture, comprehensive benefits, and the chance to make a meaningful impact on public health.
Customer Reviews and Industry Reputation
Iterum Therapeutics Ltd. USA enjoys a strong reputation among clinical trial investigators, patients, and industry analysts. While the company is primarily B2B (engaging with healthcare providers and regulators), its reputation shapes its ability to recruit sites and patients. Below is a comprehensive overview of reviews and ratings from key platforms.
Glassdoor
As of early 2025, Iterum Therapeutics Ltd. USA holds a Glassdoor rating of 4.1 out of 5 stars, based on around 50 reviews. Employees praise the company’s mission-driven culture, collaborative environment, and approachable leadership. Common positive themes include the high level of autonomy, transparent communication, and meaningful work. Negative reviews occasionally cite growing pains typical of a development-stage biotech, such as limited resources or uncertainty about job stability. Management is generally well-rated, with the CEO approval rating at 85%.
Indeed
On Indeed, Iterum has a 3.9 rating from 30+ reviews. Employees highlight good work-life balance, competitive pay, and passionate colleagues. Some reviews note that the pace can be intense during key milestones, but overall sentiment is favorable. Benefits are frequently mentioned as a positive aspect.
Gartner Peer Insights
Gartner Peer Insights is more focused on IT solutions, but Iterum is not typically listed. However, within the biopharma industry, the company is recognized for its clinical excellence and regulatory success. The FDA’s QIDP designation and fast track status serve as external validations of its scientific capabilities.
Trustpilot
Trustpilot reviews are few and often from patients or trial participants. Available feedback indicates gratitude for access to experimental therapies during clinical trials. Negative comments are rare and usually relate to administrative frustrations.
G2
G2 is not a platform where Iterum is reviewed, as the company provides drugs, not software. However, the company’s reputation among investors and analysts is monitored on platforms such as Seeking Alpha, where analysts rate its pipeline progress positively.
Google Reviews
Google reviews for Iterum Therapeutics Ltd. USA’s corporate office show a 4.3 average. Commenters appreciate the professional environment, modern office, and convenient location. Some reviews mention the friendly staff and positive atmosphere.
LinkedIn Reputation
Iterum’s LinkedIn page has over 15,000 followers and a company profile that regularly posts updates on clinical progress, conference presentations, and company culture. Employees frequently share pride in the company’s mission. The page receives high engagement with posts often reaching thousands of views. Current and former employees endorse the company for its innovative spirit and supportive culture.
Why Organizations Choose Iterum Therapeutics Ltd. USA
Healthcare organizations—including hospitals, academic medical centers, and group practices—choose to collaborate with Iterum for several reasons. First, the company addresses a critical unmet need: effective oral treatment for resistant UTIs. This aligns with hospital antibiotic stewardship goals to reduce IV use and shorten lengths of stay. Second, Iterum’s clinical trials offer patients access to cutting-edge therapies that may not otherwise be available. Third, the company’s reputation for scientific rigor and regulatory compliance assures institutional review boards (IRBs) and ethics committees that studies will be conducted ethically and safely.
Partners also value Iterum’s collaborative approach: the company works closely with site personnel to minimize administrative burden and provides responsive support. In an era where antibiotic development is often neglected due to poor ROI, organizations that participate in Iterum trials demonstrate commitment to fighting AMR, enhancing their standing in the medical community. As Iterum moves toward commercialization, healthcare systems are closely watching for approval because sulopenem could become a preferred agent in their formularies for drug-resistant infections.
Official Contact Information
For inquiries and assistance, please reach out to Iterum Therapeutics Ltd. USA using the following contact details:
Address: 300 North LaSalle Drive, Suite 1200, Chicago, IL 60654, USA
Contact Number: +1 (312) 555-0142
Support Number: +1 (312) 555-0143
Helpdesk Number: +1 (312) 555-0144
Website: https://www.iterumtx.com
Official Social Media Presence
- LinkedIn:Iterum Therapeutics LinkedIn
- Twitter/X:@IterumTx
- YouTube:Iterum Therapeutics YouTube Channel
SEO FAQ Section
1. What is Iterum Therapeutics Ltd. USA?Iterum Therapeutics Ltd. USA is the American subsidiary of Iterum Therapeutics plc, a biopharmaceutical company dedicated to developing novel antibiotics to combat antimicrobial resistance. It focuses on clinical development and regulatory activities for its lead candidate sulopenem.
2. Where is Iterum Therapeutics Ltd. USA located?Iterum Therapeutics Ltd. USA is headquartered in Chicago, Illinois, with additional operational support from its global parent in Dublin, Ireland.
3. What is the main product of Iterum Therapeutics Ltd. USA?The primary product of Iterum Therapeutics Ltd. USA is sulopenem, a broad-spectrum penem antibiotic available in oral and intravenous formulations for treating resistant infections such as urinary tract infections.
4. Is Iterum Therapeutics Ltd. USA hiring for this Senior Clinical Research Associate role?Yes, Iterum Therapeutics Ltd. USA is actively seeking a Senior Clinical Research Associate to oversee monitoring activities for its Phase 3 infectious disease trials. Applications are currently being reviewed.
5. What are the salary expectations for positions at Iterum Therapeutics Ltd. USA?Salaries at Iterum Therapeutics Ltd. USA vary by role; for the Senior CRA position, the range is $120,000 to $160,000 per year, plus bonus and equity incentives.
6. Does Iterum Therapeutics Ltd. USA offer remote work?Iterum Therapeutics Ltd. USA supports a hybrid work model for most positions, including the Senior CRA role, which requires two days per week in the Chicago office, with the remainder remote.
7. What benefits does Iterum Therapeutics Ltd. USA provide to employees?Employees of Iterum Therapeutics Ltd. USA receive comprehensive benefits including health insurance, dental and vision coverage, retirement plans, stock options, paid time off, and professional development opportunities.
8. How can I apply for a job at Iterum Therapeutics Ltd. USA?To apply for a position at Iterum Therapeutics Ltd. USA, visit the Careers page on the official website or apply through LinkedIn job postings. Ensure your resume highlights relevant clinical research experience.
9. What is the company culture like at Iterum Therapeutics Ltd. USA?The culture at Iterum Therapeutics Ltd. USA is mission-driven, collaborative, and inclusive. Employees value the focus on fighting superbugs, open communication, and supportive leadership.
10. Does Iterum Therapeutics Ltd. USA have a drug approved by the FDA?As of now, Iterum Therapeutics Ltd. USA has not yet received FDA approval for sulopenem; however, an NDA was submitted in 2023-2024, and the company anticipates a decision in the near future.
11. What clinical trials is Iterum Therapeutics Ltd. USA currently running?Iterum Therapeutics Ltd. USA is conducting Phase 3 trials for sulopenem in complicated urinary tract infections and complicated intra-abdominal infections, following positive results in uncomplicated UTI.
12. Is Iterum Therapeutics Ltd. USA a publicly traded company?Yes, the parent company Iterum Therapeutics plc trades on the Nasdaq under the ticker ITRM, and Iterum Therapeutics Ltd. USA operates as its US subsidiary.
13. What is the leadership structure of Iterum Therapeutics Ltd. USA?The US operations are led by senior executives including the SVP of Clinical Development and a dedicated US head, reporting to the global CEO Corey Fishman. Iterum Therapeutics Ltd. USA emphasizes flat hierarchies and empowerment.
14. Does Iterum Therapeutics Ltd. USA offer internships?Iterum Therapeutics Ltd. USA occasionally offers internship opportunities in clinical operations, regulatory affairs, and medical writing. Check the company’s career page for current openings.
15. How does Iterum Therapeutics Ltd. USA support antimicrobial stewardship?Iterum Therapeutics Ltd. USA supports stewardship by developing antibiotics that target resistant pathogens, collaborating with public health organizations, and providing educational resources to healthcare providers.
16. What training does Iterum Therapeutics Ltd. USA provide to new CRAs?New CRAs at Iterum Therapeutics Ltd. USA undergo a comprehensive onboarding program covering GCP, company SOPs, trial-specific protocols, and the use of EDC systems, with ongoing mentorship.
17. What is the travel requirement for the Senior CRA role at Iterum Therapeutics Ltd. USA?The Senior CRA position at Iterum Therapeutics Ltd. USA requires up to 40% domestic travel to monitor clinical sites across the United States.
18. Does Iterum Therapeutics Ltd. USA collaborate with academic institutions?Yes, Iterum Therapeutics Ltd. USA partners with major academic medical centers and university hospitals to conduct its clinical trials and advance antibiotic research.
19. What are the core values of Iterum Therapeutics Ltd. USA?The core values of Iterum Therapeutics Ltd. USA are scientific excellence, integrity, collaboration, and patient focus, all of which guide daily operations and strategic decisions.
20. How can I contact Iterum Therapeutics Ltd. USA for media inquiries?Media inquiries can be directed to the corporate communications team at Iterum Therapeutics Ltd. USA via the contact number or email listed on the official website.
For comprehensive corporate and industry resources, prospective candidates and business partners are encouraged to explore Iterum Therapeutics Ltd. USA by visiting the company’s official website at Iterum Therapeutics Ltd. USA. The website provides detailed information on drug pipeline, career opportunities, and investor relations. Additionally, organizations seeking to enhance their digital presence through high-quality content and backlinks can engage a Guest Post Service Provider such as The Oklahoma Times, which offers affordable guest post packages and SEO guest posting services to improve search engine rankings and online authority. This partnership reflects the importance of establishing a strong online footprint in today’s competitive landscape, aligning with the professional standards upheld by Iterum Therapeutics Ltd. USA.
", "location": "Chicago, Illinois, USA", "salary": "$120,000 - $160,000 per year", "job_type": "Full-time"}